@ Newsroom | SEBIO

Academic Patent Licensing Helps Drive the U.S. Economy

Posted by on Jun 23, 2017 in Newsroom | 0 comments

Just as some politicians are increasing their calls for Washington micromanagement of  the Bayh-Dole law (which allows universities and federal laboratories to license federally supported inventions for commercial development) a new study shows how impressively the current decentralized, market driven system is performing. “Thanks to the enduring effectiveness of the Bayh-Dole Act, American research universities, along with industry partners, are turning federally-funded basic research into new and valuable products that save and improve lives. The commercialization of university-based...

Read More

Registration OPEN for SEBIO Forum

Posted by on Jun 22, 2017 in Newsroom | 0 comments

Early Registration is now open for the 19th Annual  SEBIO Investor and Partnering Forum.  Come join us in Pinehurst!!  

Read More

World-leading Seqirus flu vax factory in Holly Springs hits another milestone

Posted by on Jun 22, 2017 in Newsroom | 0 comments

HOLLY SPRINGS, N.C. – The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The 550 highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs. CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and are used by manufacturers to develop and produce...

Read More

Vigilant Biosciences Announces Grant Award from National Institutes of Health

Posted by on Jun 15, 2017 in Newsroom | 0 comments

FORT LAUDERDALE, FL. – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as part of a multi-million dollar grant from the National Institutes of Health to fund research in support of a novel point of care test to improve early identification of oral and oropharyngeal cancer. The five-year study will enroll 300 mouth and throat cancer patients and control subjects in a multi-institutional setting. Institutions participating in the study include UC San...

Read More

Cocrystal Pharma Receives Investment Through Private Placement

Posted by on May 25, 2017 in Newsroom | 0 comments

ATLANTA, GA. & BOTHELL, WA. – On April 20, 2017, Cocrystal Pharma, Inc. (OTCQB: COCP) (the “Company”) closed on proceeds of $3,000,000 in a private placement offering (the “Offering”) of 12,500,000 shares of the Company’s common stock at a purchase price of $0.24 per share. The purchasers included one of the members of the Company’s board of directors, Chairman Dr. Raymond F. Schinazi. In addition, OPKO Health, Inc. invested in the Offering, of which the Company’s director Dr. Phillip Frost is Chairman and Chief Executive Officer. Cocrystal...

Read More

Florida Institute Funds Alachua-based Amend Surgical

Posted by on May 23, 2017 in Newsroom | 0 comments

GAINESVILLE and BOCA RATON, FL. – The Florida Institute for the Commercialization of Public Research (the Florida Institute) announced today that it has finalized a funding agreement with Amend Surgical, an Alachua-based medical device company with newly licensed technology developed at the University of Florida. The Florida Institute supports new company development and expansion based on publicly-funded research, and bridges early funding gaps for companies licensing technology out of Florida-based universities and research institutions. Amend Surgical is a specialty medical...

Read More